Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000411323 | SCV000486151 | likely pathogenic | Dihydropyrimidine dehydrogenase deficiency | 2016-04-05 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000411323 | SCV001162933 | pathogenic | Dihydropyrimidine dehydrogenase deficiency | 2024-03-12 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV000411323 | SCV001622847 | likely pathogenic | Dihydropyrimidine dehydrogenase deficiency | 2020-06-12 | criteria provided, single submitter | clinical testing | |
Gene |
RCV002298579 | SCV002588216 | uncertain significance | not provided | 2022-04-20 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 31589614) |
Prevention |
RCV004755907 | SCV005363038 | pathogenic | DPYD-related disorder | 2024-05-27 | no assertion criteria provided | clinical testing | The DPYD c.220C>T variant is predicted to result in premature protein termination (p.Arg74*). To our knowledge, this variant has not been previously associated with DYPD-related disease. This variant is reported in 0.16% of alleles in individuals of East Asian descent in gnomAD. Nonsense variants in DPYD are expected to be pathogenic. This variant is interpreted as pathogenic. |